'
RPG
Life sciences hosted a conference call on Oct 17, 2025. In the conference call,
the company was represented by: Mr. Vishal shah- CFO, and Mr. Ashok Nair-
Managing director.
Key takeaways of the call
In
H1 FY26, domestic formulations contributed 71% to total sales, International
Formulations 19% and APIs 10%.
Domestic
Formulations, the biggest contributor to the company’s business, recorded 13.5%
YoY sales growth in H1 FY26 driven by new products.
In Q2 FY26, Domestic Formulations outpaced the IPM by 2.2
times, recording a 17.2% YoY growth driven by strong volume.
The Domestic Formulations business continues to register
profitable and healthy growth supported by its five-pillar strategy, Product
Portfolio Rejuvenation, Strategic Brand Asset Building, deepening Customer
Coverage, Sales Force Effectiveness Augmentation, and Profitability
Improvement...
Pleaselogin & subscribe to view the full report.
More Reports
-
(05-Feb-2025)
Castrol India
Expects EBITDA margin of 22%-25% for CY25
-
(10-Feb-2023)
Deepak Nitrite
Plans capex of about Rs 1500 crore for FY23 and FY24
-
(09-Feb-2023)
Mayur Uniquoters
Targets revenue of Rs 1000 crore in FY24
-
(31-Jan-2023)
Tega industries
Capex plan is US$ 30-32 million for next three years
|
|